Home About Technology Research & Pipeline Impact Investors Partners News Careers Contact
Research & Pipeline

Science in Motion

Our structured research pipeline translates molecular biology fundamentals into actionable vaccine development milestones — transparent, rigorous, and reproducible.

Lead Program

HBsAg · Hepatitis B Model

The Hepatitis B surface antigen (HBsAg) serves as GreenHelix's primary proof-of-concept target. With over 300 million people chronically infected globally and over 820,000 deaths annually, Hepatitis B represents one of the highest-burden vaccine-preventable diseases — particularly in Sub-Saharan Africa.

Current Status
Ph.1
Active Phase
In Silico
Current Method
2024
Research Initiated
2028
Preclinical Target
Development Phases

Four-Phase Pathway

Phase 01 · Active
Construct Design & In Silico Analysis
Computational modeling of the HBsAg S-gene, codon optimization for plant expression, signal peptide selection, and in-silico secondary/tertiary structure prediction using AlphaFold2.
Gene sequence retrieval
Codon optimization
Vector design
Construct synthesis
Phase 02 · Upcoming
Experimental Validation
Agrobacterium-mediated transient expression in N. benthamiana, Western blot and ELISA-based protein detection, and initial yield quantification studies.
Agrobacterium culture
Leaf infiltration
Protein extraction
Western blot detection
Phase 03 · Planned
Expression Optimization
Systematic optimization of infiltration parameters, post-translational processing, protein purification protocols, and antigenicity confirmation through immunological assays.
Parameter optimization
Protein purification
Antigenicity assays
VLP characterization
Phase 04 · Future
Preclinical Planning
Animal model immunogenicity studies, safety evaluation, formulation development, regulatory pre-submission package preparation, and IND-enabling study design.
Animal study design
Formulation development
Safety assessment
Regulatory filing
Future Pipeline

Expansion Candidates

Malaria Antigens
RTS,S-based surface protein candidates optimized for plant expression systems
HPV Antigens
L1 VLP production for cervical cancer prevention — high African disease burden
Pandemic Response
Rapid antigen platform for novel pathogen emergence (2–4 week design cycle)
`n